Research
Hormonal
Aging is associated with an increase in pro-inflammatory adipokines and a decline in anti-inflammatory adipokines, contributing to a chronic state of low-grade systemic inflammation known as 'inflammaging'.
As you age, your fat cells release more inflammatory signals and fewer protective ones, leading to chronic low-grade inflammation. This 'inflammaging' increases the risk of diseases like diabetes and heart disease. Managing weight and staying active can help modulate these inflammatory signals.
GoodSupportsHIGH confidence
In general, the expansion of visceral adipose tissue by hypertrophy is associated with an increase in proinflammatory adipokines and a decline in anti-inflammatory mediators. With aging, nearly all adipokine levels are elevated in comparison with younger individuals with the same body fat percentage.
Why this rating
Based on a comprehensive review of adipokine changes with age.
Source
The Impact of Aging on Adipose Function and Adipokine Synthesis
Peter Mancuso et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00137
narrative_reviewCited 322×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Aging causes a redistribution of lipids from subcutaneous to visceral adipose tissue, leading to ectopic lipid storage, insulin resistance, and chronic low-grade systemic inflammation.Good
- Declining brown adipose tissue (BAT) activity with age contributes to reduced energy expenditure and increased obesity risk, mediated by reduced sympathetic output and increased FOXA3 transcription factor.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →